Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS

A Multicenter, Randomized, Double -Blind, Parallel, Comparative, Phase III Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1 Tablet in BPH Patients With LUTS

Study to investigate the efficacy and safety of GL2702 GLARS-NF1tablet and Harnal-D - tablet in benign prostatic hyperplasia patients with lower urinary tract symptomatic

GL2702 GLARS-NF1 tablet is controlled released formation which is made by GL Pharm Tech

Inclusion Criteria:

• Over 50 years old, BPH diagnosted, Adult Male Subject
• IPSS ≥ 13 point
• PSA < 4ng/mL
• 5ml/sec < Qmax ≤ 15ml/sec

Exclusion Criteria:

• Prostatic cancer
• 250ml < PVR
• ALT or AST > 2 times (Upper Normal Range)
• Total Bilirubin > 1.5 times (Upper Normal Range)
• Treated with α-adrenalin receptor blocker within 2weeks before screening
• Treated with 5Alpha-Reductase Inhibitor within 6 months before screening
• Treated with phytotherapy within 2weeks before screening
• Treated with Anabolic Steroid within 6 months before screening